Noticias y Actividades de Otsuka Holdings

Otsuka Holdings es una de las ...

• Forbes Global 2000 (#654);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Otsuka Holdings es una empresa que cotiza bajo el símbolo de cotización 4578 (JP).

Otsuka Holdings tiene presencia directa en 11 países.

Otsuka Holdings posee 23 subsidiarias incluyendo Araris Biotech, Cambridge Isotope Laboratories y Interpharma.

Ellos se encuentran en:

• Farmacia46%
• Equipos médicos29%
• Otro25%

Ver el organigrama con sus 263 ejecutivos principales

Biografías más buscadas en Otsuka Holdings

• Makoto Inoue, President and Representative Director, Chief Executi...
• Yukio Matsutani, Independent Director
• Jiro Seguchi, Outside Director and Board Member

Crear su alerta
para seguir los movimientos de los ejecutivos en Otsuka Holdings.

Otsuka Holdings tiene 3.493 competidores entre los que se incluyen UnitedHealth Group (Estados Unidos), Kaiser Permanente (Estados Unidos) y HCA (Estados Unidos).

Popular M&A news in Salud

• Hims & Hers ha Eucalyptus adquirido (publicado el 2 de junio de 2026).
• Freeman Health System ha Northwest Health adquirido (publicado el 2 de junio de 2026).
• Garner Health acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 29 de mayo de 2026).

Otros contactos sugeridos en el sector Salud

• Ari Bousbib - Chairman and Chief Executive Officer en IQVIA
• Gregory Adams - Chief Executive Officer and Chairman of the Board en Kaiser Permanente
• Pablo Legorreta - Chairman of the Board, Founder and Chief Executive Officer en Royalty Pharma

Saber más sobre el sector Salud

Últimos comunicados de prensa de Otsuka Holdings

• Otsuka Signs Joint Research Agreement with Keio UniversityIndustry-academia collaboration for infrastructure development toward the social implementation of psychedelics in Japan ｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Pharmavite Established a New Facility in Ohio, US, Dedicated to The Manufacturing of Gummy SupplementsFacilitating the Research and Development of Gummy Products｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Opens First POCARI SWEAT Factory in VietnamSupporting Health and Meeting Growing Demand｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical is Focusing on "Water, Nutrition, and Oxygen" to Tap into Human PotentialProvide "Wellness Energy" at Expo 2025 in Osaka, Kansai, Japan｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical is Expanding "Local Production and Local Recycling" of PET Bottle Initiatives in Cooperation with Local CommunitiesAgreement Signed with the Saga Eastern Environmental Facilities Association for Horizontal Recycling of PET Bottle｜New
• Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Is Now on Sale - Insurance coverage begins on March 1, 2025｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Finalizes an Agreement with Fukuroi City on the Horizontal Recycling of PET BottlesPartnering with Its Factory to Promote a "Local Production and Local Recycling" Initiative for PET Bottles｜News Releases | Otsuka Pharmaceutical Co.,
• Otsuka Sponsor TOKYO MARATHON 2025 Supporting the Conditioning of Runners Worldwide with the Global Brand POCARI SWEAT｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• View more press releases Close

Redes sociales sobre Otsuka Holdings

• Otsuka Holdings en Wikipedia, Google News y Yahoo Finance
• Otsuka Holdings en LinkedIn, Twitter y YouTube